Harvard Bioscience IncHBIO

NasdaqHealthcareLaboratory Analytical Instruments
Price (close)
$8.02
Market cap
$36.5M
P/E
—
Revenue (TTM)
$87.8M
Net income
-$10.4M
Dividend yield
—
1-year total return
82.3%
Net margin
-11.9%
Revenue growth
-1.1%
Debt / equity
4.95x

What Harvard Bioscience Inc does.

Harvard Bioscience, Inc., a Delaware corporation, is a leading developer, manufacturer and seller of technologies, products and services that enable fundamental advances in life science applications, including research, drug and therapy discovery, bioproduction and preclinical testing for pharmaceutical and therapy development. Our products and services are sold globally to customers ranging from renowned academic institutions and government laboratories to the world’s leading pharmaceutical, biotechnology and contract research organizations (“CROs”). With operations in the United States, Europe and China, we sell through a combination of direct and distribution channels to customers around the world.

Our business began in 1901, under the name Harvard Apparatus. It was founded by Dr. William T. Porter, a Professor of Physiology at Harvard Medical School and a pioneer of physiology education. We have grown over the years with the development and evolution of modern life science research and education. Our early inventions included ventilators based on Dr. Porter’s design, the mechanical syringe pump for drug infusion in the 1950s, and the microprocessor-controlled syringe pump in the 1980s. In 1996, a group of investors acquired a majority of the then existing business of our predecessor, Harvard Apparatus, Inc. Harvard Bioscience, Inc. was incorporated in the State of Delaware in September 2000 and became the successor entity to Harvard Apparatus, Inc. by merger in November 2000. In 2018, we acquired Data Sciences International, Inc. (“DSI”), a global leader in products, services and solutions focused on preclinical testing. The DSI product portfolio, which is largely complementary to our cellular and molecular technology (“CMT”) product portfolio, expanded our product portfolio to address the continuum from research and discovery to preclinical testing with principal applications in drug and therapy testing.

Revenue and profit, by fiscal year.

Fiscal year202020212022202320242025
Revenue$102.1M$118.9M$113.3M$112.3M$94.1M$86.5M
Net income-$7.8M-$288,000-$9.5M-$3.4M-$12.4M-$56.7M
Free cash flow$8.2M$67,000-$438,000$12.2M-$1.2M$5.5M

More on HBIO.

Figures from Harvard Bioscience Inc's filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.